Clinical trials: Japanese Encephalitis Virus Disease
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440
- Trial name
- NCT00596271
- Testing
- IC51, HAVRIX
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis
Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries
The primary objective is to assess the safety profile of IC51 in a pediatric population from regions where JEV is not endemic
- Trial name
- NCT01047839
- Testing
- IC51
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Japanese Encephalitis
Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) .
- Trial name
- NCT01001988
- Testing
- Blood sample, JE-CV administered in Study JEC02
- Where
- 4 sites in Philippines, Thailand
- Volunteers
- 596 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
The primary objective is to assess the systemic and local safety profile of purified inactivated Japanese Encephalitis Virus (JEV) vaccine IC51 administered in two doses in a 28 days interval up to Month 7 after the first IC51…
- Trial name
- NCT01041573
- Testing
- IC51 Japanese Encephalitis, Havrix®720, Prevnar
- Where
- 2 sites in Philippines
- Volunteers
- 1,869 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Encephalitis, Japanese Encephalitis
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults.
- Trial name
- NCT00981175
- Testing
- Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis Vaccine
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules.
- Trial name
- NCT06825312
- Testing
- Japanese Encephalitis Vaccine (Vero Cell), Inactivated, Japanese Encephalitis Vaccine, Live
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Japanese Encephalitis, Measles
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT01188343
- Testing
- Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
- Where
- 3 sites in Taiwan
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population
This is an open-label, uncontrolled phase 4 study to assess the safety and immunogenicity of the Japanese encephalitis (JE) vaccine Ixiaro® (IC51) in an elderly population.
- Trial name
- NCT01158599
- Testing
- IXIARO®
- Where
- 5 sites in Austria, Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
The aim of this study was to document the immunogenicity and safety of a booster dose of IMOJEV administered at least 12 months after the primary dose.
- Trial name
- NCT01900444
- Testing
- IMOJEV
- Where
- 8 sites in South Korea
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
This is a single-arm, non-randomized, open-label post-marketing safety observation study. The purpose of this study is to investigate the safety of JEV-I given with primary immunization in a large amount of healthy children aged…
- Trial name
- NCT06372665
- Where
- China
- Volunteers
- 15,357 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Japanese Encephalitis
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the…
- Trial name
- NCT00776230
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis, Hepatitis A
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.
- Trial name
- NCT00621764
- Testing
- Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
- Where
- 3 sites in Thailand
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years
- Trial name
- NCT00605085
- Testing
- Japanese Encephalitis purified inactivated vaccine (IC51)
- Volunteers
- 2,675 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
The study investigates the long term persistence the Japanese encephalitis vaccine IC51 and the need of a booster dose
- Trial name
- NCT00595270
- Testing
- IC51
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains…
- Trial name
- NCT00319592
- Testing
- ChimeriVax™-JE vaccine, JE-VAX® vaccine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis, Hepatitis A
Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi…
- Trial name
- NCT00735644
- Testing
- Japanese encephalitis vaccine, Japanese encephalitis vaccine (Acambis), Hepatitis A vaccine
- Where
- 8 sites in Philippines, Thailand
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
- Trial name
- NCT00594958
- Testing
- IC51
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH